Pfizer is boasting that the pharmaceutical giant is now raking in billions of dollars in profits from treating the turbo cancer epidemic that was triggered by the company’s Covid mRNA vaccines.
According to company CEO Albert Bourla, Pfizer is cashing in from new “blockbuster” cancer drugs.
Bourla, a World Economic Forum (WEF) “agenda contributor,” is gloating that treating turbo cancers is “our new Covid.”
Speaking with Fox Business about how Pfizer plans to score big on the new turbo cancer market, Bourla announced that the deadly epidemic is translating into big profits for Pfizer investors.
Since profits from the company’s mRNA (modRNA) COVID jabs are drying up, Bourla is ready to unleash new chemical drugs to reinvigorate the profit streams.
The “pandemic” brought record revenue to Pfizer, which generated an astounding $157 billion overall from not just its “vaccine” but also Paxlovid, an oral antiviral medication.
In 2023, however, sales were down by more than half at only around $71 billion.
Since the end of 2022, Pfizer’s share price has likewise fallen by 42 percent due to a rapid decline in demand for all things COVID-related.
Pfizer responded with a major cost-cutting campaign that included laying off hundreds of